Clinical Trial Results for Prostate Cancer, Early, Recurrent

2 Clinical Trials for Prostate Cancer, Early, Recurrent

Focus your search

      RECRUITING
      PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
      Description

      Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.

      Conditions
      Prostate Cancer (Post Prostatectomy)
      Talk to us
      RECRUITING
      PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
      Description

      This study will enroll 60 patients previously enrolled to MCC#18523, "A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African-American and Non-African American Men with Prostate Cancer: (VANDAAM)" that had high risk Decipher test results (Decipher score \>0.45). Patients with a high genomic classifier (GC) score at diagnosis will be approached for formal consenting for PSMA-PET imaging at 2 years post treatment.

      Conditions
      Prostate CancerRecurrent Prostate Cancer
      Talk to us